ONCY

Business Context and Reporting Period

Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Second Quarter Report)
Reporting Period: Quarter and six months ended June 30, 2005
Business Stage: Development stage biotechnology company focused on REOLYSIN®, a potential cancer therapeutic. The Company has not been profitable since inception and expects to continue incurring substantial losses until commercial viability is achieved.

Key Financial Metrics

Note: Revenue consists primarily of interest income and income from short-term investments. The Company has no operating revenue from product sales.

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by approximately $237,000 in Q2 2005 compared to Q2 2004, and by approximately $536,000 on a year-to-date basis.
• Stock-Based Compensation: A significant reduction in stock-based compensation expenses drove the lower net loss. Q2 2005 expense was $8,404 compared to $734,670 in Q2 2004.
• R&D Expenses: Total R&D expenses increased to $2,050,707 in Q2 2005 from $1,495,934 in Q2 2004. This was driven by:
  • Manufacturing: Increased to $978,298 (from $823,601) due to expanded production runs for clinical trials.
  • Clinical Trials: Increased to $549,505 (from $123,150) due to the initiation of new U.S. and U.K. trials.
• Operating Expenses: Decreased to $769,511 in Q2 2005 from $850,773 in Q2 2004, primarily due to lower costs associated with the 2004 annual report and AGM.
• Liquidity: Total cash and short-term investments increased to $31.97 million from $25.52 million in the prior year period, supported by $3.3 million in proceeds from the exercise of warrants and options.

Guidance, Outlook, and Risks

• Clinical Progress: The Company now has five active or approved clinical trials, including a Phase I systemic delivery study in the U.S. (FDA approved April 2005) and a combination radiotherapy trial in the U.K. (patient enrollment commenced subsequent to quarter end).
• Capital Resources: Management anticipates an average cash usage of approximately $1,000,000 per month. Existing capital resources are deemed adequate to fund current plans through 2007.
• Future Funding: If additional capital is required, the Company intends to raise funds primarily through the issuance of additional equity. Management notes the volatility of biotech securities and the uncertainty of raising capital when needed.
• Commitments: As of June 30, 2005, the Company has committed payments of $920,088 for product manufacturing and research collaborations, expected to be paid in 2005.
• Risks: Key risks include the speculative nature of biotech development, the efficacy and safety of REOLYSIN®, regulatory approval uncertainties, and the ability to secure future funding.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the ~$1M/month cash burn rate against the $31.9M cash balance to confirm the runway through 2007.
• Clinical Trial Milestones: Monitor the commencement of patient enrollment in the U.S. systemic trial and the U.K. combination radiotherapy trial.
• Manufacturing Costs: Track product manufacturing expenses, which are expected to increase throughout 2005 to supply the expanding trial program.
• Dilution Risk: Review the outstanding warrants (1,511,060) and options (totaling ~5M shares if fully exercised) to assess potential dilution if equity financing is required.
• Revenue Model: Confirm that revenue remains non-operating (interest income) and that no commercial product sales are imminent.